Erbitux cetuximab: Updated Phase II data

Merck's Merck Serono S.A. division reported updated data from a subset of 82 patients with wild-type K-Ras tumors from the European Phase II OPUS trial showing that Erbitux plus FOLFOX chemotherapy reduced the risk of disease progression by 43.3% vs. FOLFOX alone (p=0.0064). In a subset of 87 patients with mutant K-Ras tumors, Erbitux plus FOLFOX led to a median PFS and OS of 5.5 and 13.4 months, respectively, vs. 8.6 and 17.5 months for FOLFOX alone. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers meeting in Orlando. ...